Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Apatinib After IMRT With Concurrent Chemotherapy in High-risk Metastasis of Nasopharyngeal Carcinoma
NCT03612219Phase 2Unknown
- Start
- Jul 2018
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Rivoceranib in nasopharyngeal carcinoma (NPC) (2 arms). Primary endpoint: Progression-Free Survival at 3 years. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT03612219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03612219.